Earnings Feed
Start Free
TENAX THERAPEUTICS, INC.·4

Jan 13, 9:49 PM ET

Davidson Michael H. 4

4 · TENAX THERAPEUTICS, INC. · Filed Jan 13, 2026

Insider Transaction Report

Form 4
Period: 2026-01-09
TENAX THERAPEUTICS, INC.TENX
Davidson Michael H.
Director
Transactions
  • Award

    Stock Option (right to buy)

    2026-01-09+30,000→ 30,000 total
    Exercise: $13.30From: 2027-01-09Exp: 2036-01-09→ Common Stock (30,000 underlying)
Holdings

  • Common Stock

    2,881

  • Stock Option (right to buy)

    Exercise: $3200.00From: 2022-06-10Exp: 2031-06-10→ Common Stock (4 underlying)
    4

  • Stock Option (right to buy)

    Exercise: $992.00From: 2023-06-09Exp: 2032-06-09→ Common Stock (4 underlying)
    4

  • Stock Option (right to buy)

    Exercise: $5.94From: 2025-12-10Exp: 2034-12-10→ Common Stock (100,000 underlying)
    100,000

  • Stock Option (right to buy)

    Exercise: $5.75From: 2026-07-01Exp: 2035-07-01→ Common Stock (80,000 underlying)
    80,000

  • Pre-Funded Warrant

    [F1]
    Exercise: $0.01From: 2024-08-08→ Common Stock (47,500 underlying)
    47,500

  • Warrant

    [F2]
    Exercise: $4.50From: 2024-08-08→ Common Stock (25,000 underlying)
    25,000
Footnotes (2)
  • [F1]The pre-funded warrant has no expiration date.
  • [F2]The warrant will expire on the earlier of (i) thirty (30) trading days following the date of the Issuer's initial public announcement of topline data from its Phase 3 LEVEL Study (LEVosimendan to Improve Exercise Limitation in PH-HFpEF Patients) ( NCT05983250 ) (the "Topline Data Announcement"); (ii) proportionally upon the exercise of the Reporting Person's pre-funded warrant issued on August 8, 2024, if such exercise is prior to the Topline Data Announcement; and (iii) August 8, 2029.
Signature
/s/ S. Halle Vakani, as Attorney-in-Fact|2026-01-13

Documents

1 file
  • 4
    primary_doc.xmlPrimary

    PRIMARY DOCUMENT